A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) Given Concomitantly With Menactra™ and Adacel™ in Preadolescents and Adolescents (11 to 15 Year Olds)

MERCK & CO.INC.,0 个研究点目标入组 0 人开始时间: 2010年3月3日最近更新: 2023年9月4日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 11 至 15（—）
性别: All

入选标准

•The participant is a man or a woman, between the ages of 11 years and O days and 15 years and 364 days on the day of enrollment.
•The participant is considered to have good physical health based on medical history, physical exam, and laboratory results.
•The parent / legal guardian and the participant fully understand the study procedures, the available alternative treatments, the risks involved in the study, and voluntarily agree to participate by providing their informed consent / written consent.
•The parent / legal guardian is able to read, understand and fill out the vaccination card.
•The participant agrees to provide the study staff with a primary telephone number as well as an alternative telephone number for monitoring purposes.
•The participant must not have had their sexual initiation yet and does not plan to be sexually active during the course of the study.
•The participant must have previously received a documented primary immunization series against diphtheria, tetanus and pertussis (not in the last 5 years).

排除标准

•The participant has a known allergy to any vaccine component corresponding to the 9-valent VLP L1 vaccine against HPV, Menactra ™ or Adacel ™, such as aluminum, yeast or BENZONASE ™ (nuclease, Nycomed [used to eliminate nucleic acids residuals of this and other vaccines]). The participant experienced an allergy to an earlier dose of the combined tetanus or diphtheria vaccine or a component of whooping cough. For the purposes of this exclusion criteria, allergy means an allergic reaction that meets the criteria for serious adverse events as defined in Section 3.4.
•The participant has a condition that constitutes a contraindication for vaccination, as indicated in most of the updated Menactra and Adacel packaging inserts (including latex allergy).
•The participant has a history of severe allergic reaction (eg, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention.
•The participant has thrombocytopenia or any clotting disorder that would contraindicate intramuscular injections.
•The participant is enrolled concurrently in clinical studies of investigating agents.
•(Girls only) - The participant is pregnant (as determined by a serum pregnancy test or urine pregnancy test that is sensitive to 25 mlU / mL of p-hCG).
•The participant has donated blood within 1 week before vaccination on Day 1, or intends to donate blood during the study.
•The participant is currently immunocompromised or has been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other autoimmune condition .
•The participant has had a splenectomy.
•The participant is receiving or has received the following immunosuppressive therapies in the year prior to enrollment: radiotherapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporine, leflunomide (Arava ™), TNF-a antagonists, monoclonal antibody therapies (such as rituximab [Rituxan]), intravenous gamma globulin (IVIG), antilymphocyte serum, or other therapy that is known to interfere with the immune response.
•The participant has received any immunoglobulin products (such as RhoGAM [Ortho-Clinical Diagnostics]) or blood products within 3 months prior to vaccination on Day 1, or plans to receive any such product during the study.
•The participant has received non-replicating (inactive) vaccines within 14 days prior to vaccination on Day 1 or has received replicating (live) vaccines within 21 days prior to vaccination on Day 1.
•The participant has received a commercial HPV vaccine, or has participated in a clinical trial with an HPV vaccine and has received either the active agent or the placebo.
•The participant has received a meningococcal vaccine.
•The participant has received a booster dose of tetanus and diphtheria toxoid (Td) (Decavac ™, Adacel ™, Boostrix ™) or tetanus toxoid (TT) within the last 5 years.
•The participant has had a fever (defined as an oral temperature> 100 ° F or> 37.8 ° C) within the 24-hour period prior to vaccination on Day 1.
•The participant has a history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that could confuse the results of the study, or interfere with the intervention of the participant throughout the study, not

研究者

发起方

MERCK & CO.INC.,

相似试验

进行中（未招募）

不适用

A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPEVAX™ in Preadolescents and Adolescents (11 to 15 Year Olds)Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.MedDRA version: 12.1Level: LLTClassification code 10063001Term: Human papilloma virus infection

EUCTR2009-016218-26-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,040

进行中（未招募）

不适用

A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPEVAX™ in Preadolescents and Adolescents (11 to 15 Year Olds). - Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.MedDRA version: 12.1Level: LLTClassification code 10063001Term: Human papilloma virus infection

EUCTR2009-016218-26-BEMerck Sharp & Dohme (Europe) Inc.1,040

进行中（未招募）

1 期

Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV who are on Opiate Substitution Therapy.Hepatitis C

EUCTR2014-000343-32-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,300

进行中（未招募）

1 期

MK-5172 in Combination with MK-8742Hepatitis C

EUCTR2014-000343-32-ROMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,200

进行中（未招募）

不适用

EUCTR2009-016218-26-ATMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.1,040